| Active substance | Cobimetinib |
| Holder | Roche |
| Status | Closed |
| Indication | In combination with Zelboraf® (vemurafenib) in patients with unresectabel or metastatic BRAFV600 mutation-positive melanoma |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 28/11/2016 |
Cobimetinib®
Last updated on 13/09/2024